DCTH (Delcath Systems) Float Percentage Of Total Shares Outstanding: 91.81% (As of Jun. 30, 2026)


DCTH Delcath Systems Inc DCTH
70 GF Score
Price $12.59
GF Value $36.72
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Delcath Systems Float Percentage Of Total Shares Outstanding?

Delcath Systems DCTH -2.78% 70 Float Percentage Of Total Shares Outstanding is 91.81% as of Jun. 30, 2026. GuruFocus rates DCTH with a GF Score™ of 70/100 and a GF Value™ of $36.72 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Delcath Systems's float shares is 31.69 Mil. Delcath Systems's total shares outstanding is 34.52 Mil. Delcath Systems's float percentage of total shares outstanding is 91.81%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Delcath Systems's Insider Ownership is 16.57%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Delcath Systems's Institutional Ownership is 52.23%.

DCTH
70GF Score
Delcath Systems Inc DCTH
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Delcath Systems Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Delcath Systems's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=31.69/34.52
=91.81%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 91.81% mean?
Delcath Systems (DCTH) has a Float Percentage Of Total Shares Outstanding of 91.81% as of Jun. 30, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Delcath Systems and its competitors.
Is Delcath Systems' Float Percentage Of Total Shares Outstanding too high?
Delcath Systems' current Float Percentage Of Total Shares Outstanding is 91.81%. Overall, Delcath Systems has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Delcath Systems' Float Percentage Of Total Shares Outstanding compare to VMD and VREX?
Delcath Systems' Float Percentage Of Total Shares Outstanding of 91.81% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Medical Devices & Instruments company?
A good Float Percentage Of Total Shares Outstanding depends on the Medical Devices & Instruments industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Delcath Systems and its competitors. Delcath Systems's current Float Percentage Of Total Shares Outstanding is 91.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Delcath Systems stock overvalued right now?
Based on GuruFocus' analysis, Delcath Systems (DCTH) is currently considered Significantly Undervalued. The stock's GF Value™ is $36.72, compared to a current price of $12.59 — trading 65.7% below its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 91.81%. Delcath Systems' overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Delcath Systems (DCTH), the current Float Percentage Of Total Shares Outstanding is 91.81% as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Delcath Systems (DCTH) Overvalued in 2026?

Based on GuruFocus' analysis, Delcath Systems stock appears to be undervalued. The current stock price of $12.59 is trading 65.7% below its estimated GF Value™ of $36.72. GuruFocus considers Delcath Systems to be Significantly Undervalued.

Key valuation signals for DCTH:

  • Float Percentage Of Total Shares Outstanding: 91.81%
  • GF Value™: $36.72 vs. price of $12.59 (65.7% below fair value)
  • GF Score™: 70/100 with 4 warning signs

No single metric tells the full story. See the DCTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Delcath Systems Business Description

Other Exchanges DV3R:Germany
Address 566 Queensbury Avenue, Queensbury, NY, USA, 12804
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
70GF Score

Get the complete analysis for DCTH

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.59
Price
$36.72
GF Value